Among other therapeutic targets currently in investigation for CAD, we found that lower levels of ANGPTL4 were causally associated with increased risk of ankylosing spondylitis (Figure 4D) in addition to expected associations with cardiovascular and lipid phenotypes, which is consistent with a previous finding linking the ANGPTL4 E40K partial loss-of-function variant with increased risk of ankylosing spondylitis.49 Here, ANGPTL4 is linked to ankylosing spondylitis.